Janice MacLennan, pharma strategy consultant and founder & CEO, Nmblr answers the question: will 2026 signal the end of business-as-usual in biopharma commercialisation?
Michael Pfeifer, senior expert adaptive safety and Alexander Kurdas, expert for machinery and electrical safety, TÜV SÜD, share insights on ensuring safer pharma facilities.
Sofia Sotiropoulou, senior director of Sustainability and Climate Innovation at Lonza Capsugel shares thoughts on the current state of sustainability in the industry.
Shannon Ryan, senior director of application services at Avantor, describes why traditional buffer preparation models are increasingly strained at large scale.
Sonia Schwantes, market and technical development director for NewAge Industries, looks at reducing Scope 1, Scope 2, and Scope 3 emissions innovatively.
In February 2025, Future Biogas and AstraZeneca launched the UK’s first unsubsidised biomethane plant at Gonerby Moor. A year on, CEO Philipp Lukas explains why it proves green gas can scale without government support.
Mark Schofield, director, R&D, and Nick Marchand, senior manager, Cytiva, share how modern filtration innovations are driving intensified bioprocessing, boosting efficiency, and supporting sustainability across emerging modalities.
In this article CurTec, explores how a prepared approach to secondary bulk packaging supports predictable performance, audit confidence and continuity across biopharma supply chains.
